Eli Lilly to Invest €330m in Cork Biopharmaceutical Facility

The investment will expand the Kinsale site’s existing biopharmaceutical mission with the establishment of an additional world-class commercialization and manufacturing facility.

When fully operational, the new plant will require up to 200 highly skilled employees. Also, a further 300 construction jobs will be created on the site during building works. The planned 240,000-sq ft biopharmaceutical commercialization and manufacturing facility announced today will further enhance the company’s ability to bring treatments for illnesses such as cancer and diabetes to patients worldwide.

This is the second significant investment Lilly has made at its Kinsale site in recent years. In 2006, the company announced a €300m investment in its first biopharmaceutical manufacturing and new-product commercialization facility at its Kinsale campus, which came on stream in 2010.

Speaking at the announcement, Minister Bruton said: “The Action Plan for Jobs, which the Government published recently, outlined a range of measures which we will take in 2012 to target the high-end manufacturing and health/life sciences sectors for further growth and also to deepen and develop the impact of multinational companies in Ireland. Today’s announcement — that this world-leading company is making a substantial investment in expanding its facility in Kinsale with the creation of up to 200 permanent jobs — shows what is possible in these areas.

“The Government is determined to ensure that more announcements like this become real in the coming years,” Bruton added. “By implementing the Action Plan for Jobs, we can support more businesses, rebuild the economy and create the jobs we desperately need.”